Imatinib mesylate and the management of chronic myeloid leukemia (CML)
Ebru Koca, İbrahim C. HaznedaroğluDepartment Of Internal Medicine, Hematology Unit, Hacettepe University School Of Medicine, Ankara, TurkeyKeywords: Chronic myeloid leukemia (CML), Imatinib mesylate, BCR-ABL, Signal transduction inhibitor.
Ebru Koca, İbrahim C. Haznedaroğlu. Imatinib mesylate and the management of chronic myeloid leukemia (CML). . 2005; 22(4): 161-172
Corresponding Author: İbrahim C. Haznedaroğlu, Türkiye
Corresponding Author: İbrahim C. Haznedaroğlu, Türkiye
| TOOLS |
 Full Text PDF Print Download citation RIS EndNote BibTex Medlars Procite Reference Manager Share with email Share Send email to author
Similar articles Google Scholar |